Lupin Signs Global Semaglutide Deal with Galenicum Across 23 Countries

Lupin Ltd. has announced a strategic partnership with Galenicum Health to expand its global presence in diabetes and obesity care. The agreement, signed via Lupin Atlantis Holdings SA, focuses on injectable Semaglutide, a GLP-1 receptor agonist widely recognized for its effectiveness in managing diabetes and weight reduction.

Key Highlights:

• Geographic Scope: The agreement spans 23 countries, including Canada, Europe, Southeast Asia, and Latin America.
• Role Allocation:
• Galenicum Health will oversee development, manufacturing, and supply.
• Lupin will manage regulatory submissions, approvals, commercialization, and distribution.
• Strategic Value: Strengthens Lupin’s portfolio in the fast-growing GLP-1 therapy segment.
• Market Expansion: Enables Lupin to leverage its commercial presence beyond India into high-demand regions.
• Therapeutic Importance: Semaglutide is considered a breakthrough therapy, offering improved glycemic control and weight management benefits.

This collaboration highlights Lupin’s ambition to become a global leader in chronic disease management, while Galenicum’s expertise ensures robust development and supply capabilities.

Sources: CNBC-TV18, Business Standard, Reuters